Wealth Management Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealth Management Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,725	Closed	-$263K	–	205
2023 Q4	$263K	Hold	2,725	–	–	0.14%	157
2023 Q3	$241K	Buy	2,725 +285	+12%	+$25.4K	0.14%	154
2023 Q2	$211K	Sell	2,440 -182	-7%	-$17.1K	0.12%	174
2023 Q1	$255K	Sell	2,622 -706	-21%	-$73.2K	0.16%	152
2022 Q4	$344K	Sell	3,328 -1,789	-35%	-$168K	0.23%	102
2022 Q3	$434K	Hold	5,117	–	–	0.31%	90
2022 Q2	$424K	Hold	5,117	–	–	0.29%	88
2022 Q1	$395K	Hold	5,117	–	–	0.22%	116
2021 Q4	$452K	Buy	5,117 +1,691	+49%	+$140K	0.24%	109
2021 Q3	$265K	Buy	3,426 +902	+36%	+$71.2K	0.15%	150
2021 Q2	$211K	Buy	+2,524	New	+$200K	0.12%	188

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wealth Management Associates's BMRN Position: Q1 2024 in Review

Wealth Management Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,725 shares — an estimated $263K sold.

Wealth Management Associates first reported a position in BMRN in Q2 2021 and held it in 11 quarters. The position peaked at $452K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Wealth Management Associates reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Wealth Management Associates sold 2,725 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $263K.
Wealth Management Associates first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 11 quarters.
Wealth Management Associates's BioMarin Pharmaceuticals position peaked at $452K in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Wealth Management Associates's 13F filing for Q1 2024, filed 28 May 2025.